190 related articles for article (PubMed ID: 31092732)
1. Transplantation of donor grafts with defined ratio of conventional and regulatory T cells in HLA-matched recipients.
Meyer EH; Laport G; Xie BJ; MacDonald K; Heydari K; Sahaf B; Tang SW; Baker J; Armstrong R; Tate K; Tadisco C; Arai S; Johnston L; Lowsky R; Muffly L; Rezvani AR; Shizuru J; Weng WK; Sheehan K; Miklos D; Negrin RS
JCI Insight; 2019 May; 4(10):. PubMed ID: 31092732
[TBL] [Abstract][Full Text] [Related]
2. Single-center randomized trial of T-reg graft alone vs T-reg graft plus tacrolimus for the prevention of acute GVHD.
Bader CS; Pavlova A; Lowsky R; Muffly LS; Shiraz P; Arai S; Johnston LJ; Rezvani AR; Weng WK; Miklos DB; Frank MJ; Tamaresis JS; Agrawal V; Bharadwaj S; Sidana S; Shizuru JA; Fernhoff NB; Putnam A; Killian S; Xie BJ; Negrin RS; Meyer EH
Blood Adv; 2024 Mar; 8(5):1105-1115. PubMed ID: 38091578
[TBL] [Abstract][Full Text] [Related]
3. Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation.
Di Ianni M; Falzetti F; Carotti A; Terenzi A; Castellino F; Bonifacio E; Del Papa B; Zei T; Ostini RI; Cecchini D; Aloisi T; Perruccio K; Ruggeri L; Balucani C; Pierini A; Sportoletti P; Aristei C; Falini B; Reisner Y; Velardi A; Aversa F; Martelli MF
Blood; 2011 Apr; 117(14):3921-8. PubMed ID: 21292771
[TBL] [Abstract][Full Text] [Related]
4. Effect of Sirolimus on Immune Reconstitution Following Myeloablative Allogeneic Stem Cell Transplantation: An Ancillary Analysis of a Randomized Controlled Trial Comparing Tacrolimus/Sirolimus and Tacrolimus/Methotrexate (Blood and Marrow Transplant Clinical Trials Network/BMT CTN 0402).
Gooptu M; Kim HT; Howard A; Choi SW; Soiffer RJ; Antin JH; Ritz J; Cutler CS
Biol Blood Marrow Transplant; 2019 Nov; 25(11):2143-2151. PubMed ID: 31271885
[TBL] [Abstract][Full Text] [Related]
5. Altered regulatory T cell homeostasis in patients with CD4+ lymphopenia following allogeneic hematopoietic stem cell transplantation.
Matsuoka K; Kim HT; McDonough S; Bascug G; Warshauer B; Koreth J; Cutler C; Ho VT; Alyea EP; Antin JH; Soiffer RJ; Ritz J
J Clin Invest; 2010 May; 120(5):1479-93. PubMed ID: 20389017
[TBL] [Abstract][Full Text] [Related]
6. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
7. Sirolimus-based graft-versus-host disease prophylaxis promotes the in vivo expansion of regulatory T cells and permits peripheral blood stem cell transplantation from haploidentical donors.
Peccatori J; Forcina A; Clerici D; Crocchiolo R; Vago L; Stanghellini MT; Noviello M; Messina C; Crotta A; Assanelli A; Marktel S; Olek S; Mastaglio S; Giglio F; Crucitti L; Lorusso A; Guggiari E; Lunghi F; Carrabba M; Tassara M; Battaglia M; Ferraro A; Carbone MR; Oliveira G; Roncarolo MG; Rossini S; Bernardi M; Corti C; Marcatti M; Patriarca F; Zecca M; Locatelli F; Bordignon C; Fleischhauer K; Bondanza A; Bonini C; Ciceri F
Leukemia; 2015 Feb; 29(2):396-405. PubMed ID: 24897508
[TBL] [Abstract][Full Text] [Related]
8. Immunoselection and clinical use of T regulatory cells in HLA-haploidentical stem cell transplantation.
Di Ianni M; Falzetti F; Carotti A; Terenzi A; Del Papa B; Perruccio K; Ruggeri L; Sportoletti P; Rosati E; Marconi P; Falini B; Reisner Y; Velardi A; Aversa F; Martelli MF
Best Pract Res Clin Haematol; 2011 Sep; 24(3):459-66. PubMed ID: 21925099
[TBL] [Abstract][Full Text] [Related]
9. Allogeneic hematopoietic cell transplantation without myeloablative conditioning for patients with advanced hematologic malignancies.
Gürman G; Arat M; Ilhan O; Konuk N; Beksaç M; Celebi H; Ozcan M; Arslan O; Ustün C; Akan H; Uysal A; Koç H
Cytotherapy; 2001; 3(4):253-60. PubMed ID: 12171713
[TBL] [Abstract][Full Text] [Related]
10. Single infusion of donor mononuclear early apoptotic cells as prophylaxis for graft-versus-host disease in myeloablative HLA-matched allogeneic bone marrow transplantation: a phase I/IIa clinical trial.
Mevorach D; Zuckerman T; Reiner I; Shimoni A; Samuel S; Nagler A; Rowe JM; Or R
Biol Blood Marrow Transplant; 2014 Jan; 20(1):58-65. PubMed ID: 24140121
[TBL] [Abstract][Full Text] [Related]
11. Allogeneic transplantation of positively selected peripheral blood CD34+ progenitor cells from matched related donors.
Finke J; Brugger W; Bertz H; Behringer D; Kunzmann R; Weber-Nordt RM; Kanz L; Mertelsmann R
Bone Marrow Transplant; 1996 Dec; 18(6):1081-6. PubMed ID: 8971376
[TBL] [Abstract][Full Text] [Related]
12. CD34+ Stem Cell Selection and CD3+ T Cell Add-Back from Matched Unrelated Adult Donors in Children with Primary Immunodeficiencies and Hematological Diseases.
Porta F; Comini M; Soncini E; Carracchia G; Maffeis M; Pintabona V; Bolda F; Beghin A; Schumacher RF; Lanfranchi A
Transplant Cell Ther; 2021 May; 27(5):426.e1-426.e9. PubMed ID: 33965183
[TBL] [Abstract][Full Text] [Related]
13. CD3+/Tregs ratio in donor grafts is linked to acute graft-versus-host disease and immunologic recovery after allogeneic peripheral blood stem cell transplantation.
Pastore D; Delia M; Mestice A; Carluccio P; Perrone T; Gaudio F; Curci P; Rossi AR; Ricco A; Specchia G
Biol Blood Marrow Transplant; 2012 Jun; 18(6):887-93. PubMed ID: 22062803
[TBL] [Abstract][Full Text] [Related]
14. Allogeneic bone marrow grafts with high levels of CD4(+) CD25(+) FoxP3(+) T cells can lead to engraftment failure.
Fricke S; Rothe K; Hilger N; Ackermann M; Oelkrug C; Fricke C; Schönfelder U; Niederwieser D; Emmrich F; Sack U
Cytometry A; 2012 Jun; 81(6):476-88. PubMed ID: 22522779
[TBL] [Abstract][Full Text] [Related]
15. Total Body Irradiation-Based Myeloablative Haploidentical Stem Cell Transplantation Is a Safe and Effective Alternative to Unrelated Donor Transplantation in Patients Without Matched Sibling Donors.
Solomon SR; Sizemore CA; Sanacore M; Zhang X; Brown S; Holland HK; Morris LE; Bashey A
Biol Blood Marrow Transplant; 2015 Jul; 21(7):1299-307. PubMed ID: 25797174
[TBL] [Abstract][Full Text] [Related]
16. Impact of donor age on outcome after allogeneic hematopoietic cell transplantation.
Rezvani AR; Storer BE; Guthrie KA; Schoch HG; Maloney DG; Sandmaier BM; Storb R
Biol Blood Marrow Transplant; 2015 Jan; 21(1):105-12. PubMed ID: 25278458
[TBL] [Abstract][Full Text] [Related]
17. Prophylactic growth factor-primed donor lymphocyte infusion using cells reserved at the time of transplantation after allogeneic peripheral blood stem cell transplantation in patients with high-risk hematologic malignancies.
Sohn SK; Jung JT; Kim DH; Lee NY; Seo KW; Chae YS; Park SW; Kim JG; Suh JS; Lee KB
Cancer; 2002 Jan; 94(1):18-24. PubMed ID: 11815956
[TBL] [Abstract][Full Text] [Related]
18. Donor CD4+ Foxp3+ regulatory T cells are necessary for posttransplantation cyclophosphamide-mediated protection against GVHD in mice.
Ganguly S; Ross DB; Panoskaltsis-Mortari A; Kanakry CG; Blazar BR; Levy RB; Luznik L
Blood; 2014 Sep; 124(13):2131-41. PubMed ID: 25139358
[TBL] [Abstract][Full Text] [Related]
19. [Effects of graft compositions on hematopoietic reconstitution and graft-versus-host disease in related donor peripheral blood stem cell transplantation].
Zhan Y; Yi ZS; Wei YQ; Huang F; Zhang YM; Fan ZP; Feng R
Zhonghua Xue Ye Xue Za Zhi; 2008 May; 29(5):333-6. PubMed ID: 18844073
[TBL] [Abstract][Full Text] [Related]
20. IL-2 promotes early Treg reconstitution after allogeneic hematopoietic cell transplantation.
Betts BC; Pidala J; Kim J; Mishra A; Nishihori T; Perez L; Ochoa-Bayona JL; Khimani F; Walton K; Bookout R; Nieder M; Khaira DK; Davila M; Alsina M; Field T; Ayala E; Locke FL; Riches M; Kharfan-Dabaja M; Fernandez H; Anasetti C
Haematologica; 2017 May; 102(5):948-957. PubMed ID: 28104702
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
